基因合成市场－全球产业规模、份额、趋势、机会、预测（按方法、服务、应用、最终用途、地区和竞争格局划分，2021-2031年）

全球基因合成市场预计将从 2025 年的 21.1 亿美元成长到 2031 年的 37.3 亿美元，复合年增长率为 9.96%。

基因合成是指不依赖天然模板，从头建构双股DNA序列的化学方法，它能够精确地建构复杂的基因和基因组，用于生物学研究。这一成长主要受以下因素驱动：对个人化治疗策略日益增长的需求、疫苗快速研发的迫切需要，以及生命科学领域为支持研发活动而注入的大量资金。 SynBioBeta的报告也印证了这项资金復苏的趋势：到2024年，合成生物学领域的创投将达到122亿美元，显示强劲的资金筹措水准对于维持产业扩张和加速技术突破至关重要。

儘管前景乐观，但合成DNA潜在的滥用所带来的生物安全风险，仍构成市场面临的重大障碍。对意外或恶意製造危险病原体的担忧，迫使各国政府和国际组织实施严格的法规结构和筛检程序。这些强制性合规措施给製造商带来了高昂的营运成本和沈重的行政负担，可能导致生产延误，并阻碍全球基因合成市场的更广泛应用。

市场驱动因素

高通量DNA合成技术的进步正显着加速合成生物学在工业和科研领域的应用。硅基和酶促合成技术的进步使得复杂、高精度基因序列的快速、大规模生产成为可能，从根本上打破了传统设计-构建-测试-学习循环的限制。这种扩充性使得商业供应商能够满足日益增长的需求，因为越来越多的研究人员将突变体库和代谢途径的建构外包出去。例如，Twist Biosciences在其2024年11月发布的「2024财年第四季及全年」财务报告中披露，该公司在该财年交付了约77.2万个基因。与上一时期相比，这显示可扩展合成技术的应用显着增加。

此外，基因和细胞疗法临床开发平臺的不断扩展正在推动市场发展，从而持续催生对GMP级合成DNA的需求，而合成DNA对于病毒载体生产和mRNA治疗模板至关重要。随着製药公司推进候选药物从发现阶段进入受监管的临床试验，对精准遗传物质的需求也稳定成长，以确保治疗的安全性和有效性。根据美国基因和细胞治疗学会（ASGCT）于2024年4月发布的《2024年第一季基因、细胞和RNA疗法现况报告》，全球基因、细胞和RNA治疗方法开发平臺已扩展至4016种，凸显了对原料的庞大需求。为了支持这一成长，新参与企业正利用投资者的兴趣扩大其生产能力。例如，Elegen在2024年完成了3,500万美元的B轮资金筹措，用于将其专有的无细胞DNA生产基础设施商业化。

市场挑战

全球基因合成市场面临源自生物安全威胁的重大挑战，这些威胁与合成DNA潜在的滥用有关。对危险病原体设计的担忧促使人们实施严格的法律规范和筛检通讯协定。这些合规要求迫使製造商在其工作流程中加入昂贵且耗时的检验系统，从而直接增加营运成本并延长产品交付时间。

这些安全措施的负担对市场的柔软性和扩充性造成了不成比例的影响。企业不得不将大量资源投入政府的审查程序和「了解你的客户」（KYC）检验中，而不是专注于生产速度和创新。正如国际基因合成联盟在2024年指出的那样，超过40家领先的基因合成供应商已承诺遵守统一的筛检通讯协定，以符合这些严格的生物安全标准。虽然这种广泛的合规性对于确保公共至关重要，但程序上的复杂性阻碍了生产效率，并限制了整个基因合成产业的成长潜力。

市场趋势

DNA资料储存是一项新兴应用，它透过解决传统数位存檔的严重局限性，正在改变市场格局。随着全球数据生成量超过磁性及硅基储存介质的容量，合成DNA凭藉其卓越的体积密度和耐久性，成为储存数千年资讯的理想替代方案。该应用需要合成大量的编码寡核苷酸，这为基因合成供应商创造了一条新的、利润丰厚的收入来源，而不仅限于生物研究的需求。例如，在2025年5月题为「DNA资料储存业务分拆为独立公司」的新闻稿中，Twist Biosciences宣布已为其新成立的子公司Atlas Data Storage筹集了1.55亿美元的种子资金，旨在将这项存檔技术推向市场，并满足日益增长的长期资料储存需求。

分散式桌上型DNA列印平台的广泛应用正推动着服务模式从集中式转变为现场生产的根本性转变。实验室越来越多地部署自动化合成设备，在现场生产遗传物质，消除运输延误，并降低外包带来的智慧财产权风险。这种转变使研究人员能够快速迭代设计，缩短疫苗开发和代谢工程计划的周期，而无需依赖外部供应商。根据2025年3月发布的公告“Telesis Bio从Novalis Life Sciences和Northpond Ventures融资2100万美元”，Telesis Bio获得这笔资金的目的是加速其自动化台式合成系统的商业化部署，这凸显了该行业向分布式生产能力的战略转型。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球基因合成市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依方法（固相合成、晶片合成、PCR酶合成）
  • 依服务项目（抗体DNA合成、病毒DNA合成等）
  • 按应用领域（基因/细胞疗法开发、疫苗开发、疾病诊断等）
  • 依最终用户（生技/製药公司、学术/政府研究机构、受託研究机构）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美基因合成市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲基因合成市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区基因合成市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲基因合成市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲基因合成市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球基因合成市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• OriGene Technologies, Inc.
• Integrated DNA Technologies, Inc.
• ProMab Biotechnologies, Inc.
• Thermo Fisher Scientific, Inc.
• ProteoGenix, Inc.
• Biomatik USA LLC
• Twist Bioscience Corp.
• Boster Biological Technology Inc.
• Brooks Automation, Inc.
• Genscript Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Gene Synthesis Market is projected to expand from USD 2.11 Billion in 2025 to USD 3.73 Billion by 2031, registering a compound annual growth rate of 9.96%. Gene synthesis entails the de novo chemical engineering of double-stranded DNA sequences independent of natural templates, facilitating the precise creation of complex genes and genomes for biological investigation. This growth is largely fueled by the rising demand for personalized therapeutic strategies, the urgent requirement for rapid vaccine formulation, and substantial capital injections into the life sciences domain that support research and development activities. Highlighting this financial resurgence, SynBioBeta reported that venture investment in the synthetic biology sector hit $12.2 billion in 2024, indicating robust funding levels essential for sustaining industrial expansion and fostering technological breakthroughs.

Despite this favorable outlook, the market encounters substantial hurdles related to biosecurity risks linked to the potential exploitation of synthetic DNA. Anxieties regarding the accidental or malicious generation of dangerous pathogens have compelled governments and international organizations to enforce strict regulatory frameworks and screening procedures. These mandatory compliance measures impose higher operational expenses and significant administrative loads on manufacturers, leading to potential production delays and hindering the broader proliferation of the global gene synthesis market.

Market Driver

Improvements in high-throughput DNA synthesis technologies are markedly speeding up the integration of synthetic biology into both industrial and research environments. Advances in silicon-based and enzymatic synthesis enable the large-scale production of complex, high-fidelity gene sequences with faster turnaround times, effectively eliminating past constraints in the design-build-test-learn cycle. This operational scalability permits commercial suppliers to satisfy the growing volume demands of researchers who are increasingly outsourcing the creation of variant libraries and metabolic pathways. For instance, Twist Bioscience revealed in its "Twist Bioscience Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results" from November 2024 that it shipped roughly 772,000 genes over the fiscal year, signaling a significant rise in the adoption of scalable synthesis technologies compared to previous periods.

The market is further bolstered by the broadening clinical development pipelines for gene and cell therapies, which generate a continuous demand for GMP-grade synthetic DNA essential for viral vector production and mRNA therapeutic templates. As pharmaceutical entities progress candidates from discovery stages to regulated clinical trials, the need for exact genetic materials to guarantee therapeutic safety and efficacy grows steadily. According to the "Gene, Cell, & RNA Therapy Landscape: Q1 2024 Quarterly Report" by the American Society of Gene + Cell Therapy in April 2024, the global pipeline has swelled to encompass 4,016 gene, cell, and RNA therapies, highlighting the immense raw material requirements. To support this growth, new market players are leveraging investor interest to expand manufacturing capabilities; for example, Elegen raised $35 million in Series B financing in 2024 to commercialize its proprietary cell-free DNA manufacturing infrastructure.

Market Challenge

The global gene synthesis market faces considerable obstacles arising from biosecurity threats linked to the possible misuse of synthetic DNA. Worries over the engineering of hazardous pathogens have mandated the implementation of rigorous regulatory structures and screening protocols. These compliance requirements compel manufacturers to incorporate expensive and time-intensive verification systems into their workflows, which directly elevates operational overhead and prolongs product delivery schedules.

The weight of these security precautions disproportionately impacts market flexibility and scalability. Firms are required to dedicate significant resources to administrative vetting procedures and "Know Your Customer" verifications instead of focusing solely on production velocity or technological innovation. As noted by the International Gene Synthesis Consortium in 2024, over 40 leading gene synthesis providers have pledged adherence to the Harmonized Screening Protocol to comply with these stringent biosecurity norms. While such widespread compliance is essential for ensuring public safety, the consequent rise in procedural intricacy serves as a hindrance to manufacturing efficiency, thereby curbing the overall growth potential of the gene synthesis industry.

Market Trends

The rise of DNA data storage as a new application vertical is transforming the market by tackling the severe constraints of conventional digital archiving. With global data generation exceeding the capabilities of magnetic and silicon-based storage media, synthetic DNA presents an alternative boasting superior volumetric density and durability, capable of preserving information for thousands of years. This application necessitates the synthesis of immense volumes of coding oligonucleotides, generating a fresh high-volume revenue source for gene synthesis providers separate from biological research requirements. For example, Twist Bioscience announced in a May 2025 press release titled "Twist Bioscience Spins Out DNA Data Storage as Independent Company" that it had obtained $155 million in seed funding for its new subsidiary, Atlas Data Storage, to bring this archival technology to market and address the rising demand for long-term data preservation.

A fundamental shift from centralized service models to on-site manufacturing is being driven by the adoption of decentralized benchtop DNA printing platforms. Laboratories are increasingly incorporating automated synthesizers to manufacture genetic material within their own facilities, thereby removing shipping delays and reducing intellectual property risks linked to outsourcing. This change enables researchers to iterate designs swiftly, shortening development timelines for vaccines and metabolic engineering initiatives without dependence on external suppliers. According to a March 2025 announcement titled "Telesis Bio Raises $21 Million from Novalis LifeSciences and Northpond Ventures," Telesis Bio secured this funding specifically to hasten the commercial rollout of its automated benchtop synthesis systems, emphasizing the industry's strategic move toward distributed manufacturing capabilities.

Key Market Players

• OriGene Technologies, Inc.
• Integrated DNA Technologies, Inc.
• ProMab Biotechnologies, Inc.
• Thermo Fisher Scientific, Inc.
• ProteoGenix, Inc.
• Biomatik USA LLC
• Twist Bioscience Corp.
• Boster Biological Technology Inc.
• Brooks Automation, Inc.
• Genscript Corporation

Report Scope

In this report, the Global Gene Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Synthesis Market, By Method

• Solid-phase Synthesis
• Chip-based Synthesis
• PCR-based Enzyme Synthesis

Gene Synthesis Market, By Service

• Antibody DNA Synthesis
• Viral DNA Synthesis
• Others

Gene Synthesis Market, By Application

• Gene & Cell Therapy Development
• Vaccine Development
• Disease Diagnosis
• Others

Gene Synthesis Market, By End Use

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations

Gene Synthesis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Synthesis Market.

Available Customizations:

Global Gene Synthesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Synthesis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Method (Solid-phase Synthesis, Chip-based Synthesis, PCR-based Enzyme Synthesis)
  • 5.2.2. By Service (Antibody DNA Synthesis, Viral DNA Synthesis, Others)
  • 5.2.3. By Application (Gene & Cell Therapy Development, Vaccine Development, Disease Diagnosis, Others)
  • 5.2.4. By End Use (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Contract Research Organizations)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Gene Synthesis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Method
  • 6.2.2. By Service
  • 6.2.3. By Application
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gene Synthesis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Method
      • 6.3.1.2.2. By Service
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Gene Synthesis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Method
      • 6.3.2.2.2. By Service
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Gene Synthesis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Method
      • 6.3.3.2.2. By Service
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End Use

7. Europe Gene Synthesis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Method
  • 7.2.2. By Service
  • 7.2.3. By Application
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gene Synthesis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Method
      • 7.3.1.2.2. By Service
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End Use
  • 7.3.2. France Gene Synthesis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Method
      • 7.3.2.2.2. By Service
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Gene Synthesis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Method
      • 7.3.3.2.2. By Service
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Gene Synthesis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Method
      • 7.3.4.2.2. By Service
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Gene Synthesis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Method
      • 7.3.5.2.2. By Service
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End Use

8. Asia Pacific Gene Synthesis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Method
  • 8.2.2. By Service
  • 8.2.3. By Application
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gene Synthesis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Method
      • 8.3.1.2.2. By Service
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Gene Synthesis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Method
      • 8.3.2.2.2. By Service
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan Gene Synthesis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Method
      • 8.3.3.2.2. By Service
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea Gene Synthesis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Method
      • 8.3.4.2.2. By Service
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Gene Synthesis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Method
      • 8.3.5.2.2. By Service
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End Use

9. Middle East & Africa Gene Synthesis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Method
  • 9.2.2. By Service
  • 9.2.3. By Application
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gene Synthesis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Method
      • 9.3.1.2.2. By Service
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE Gene Synthesis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Method
      • 9.3.2.2.2. By Service
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa Gene Synthesis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Method
      • 9.3.3.2.2. By Service
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End Use

10. South America Gene Synthesis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Method
  • 10.2.2. By Service
  • 10.2.3. By Application
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gene Synthesis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Method
      • 10.3.1.2.2. By Service
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia Gene Synthesis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Method
      • 10.3.2.2.2. By Service
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina Gene Synthesis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Method
      • 10.3.3.2.2. By Service
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gene Synthesis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. OriGene Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Integrated DNA Technologies, Inc.
• 15.3. ProMab Biotechnologies, Inc.
• 15.4. Thermo Fisher Scientific, Inc.
• 15.5. ProteoGenix, Inc.
• 15.6. Biomatik USA LLC
• 15.7. Twist Bioscience Corp.
• 15.8. Boster Biological Technology Inc.
• 15.9. Brooks Automation, Inc.
• 15.10. Genscript Corporation

16. Strategic Recommendations

17. About Us & Disclaimer